Stock Ratings / Health Care / MCRB / insiders

PBM (46) ACTU (35) KYNB (32) AKTX (37) ⌘ Pro Terminal →

Seres Therapeutics Inc. (MCRB) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Are MCRB insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies MCRB leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

$1.77 -9.23% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.74

Seres Therapeutics Inc. (MCRB) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $17.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MCRB Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MCRB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Seres Therapeutics Inc. (NASDAQ: MCRB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.77 (-9.23% 1D, market cap $17.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, MCRB ranks #470 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MCRB compare to PBM and ACTU in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MCRB carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PBM (Psyence Biomedical Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $17.6M) and ACTU (Actuate Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $18.4M). Among the 5-stock peer group, MCRB leads on earnings multiple (N/A) while MCRB leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MCRB?

▼

Per MCRB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001609809), Seres Therapeutics Inc. generated $789.0K in revenue, $5.7M in net income, and $865.0K in free cash flow against $138.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.74 (-1.85%)🧬 Cannibal Buyback (-0.68% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 86.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MCRB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY MCRB SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+10/20 pts (25% of score)

SEC Form 4 / 13F Thermometer: 50% Net Buy • Cannibal Buyback (-0.68% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.53-8.7% Next Q

Q2 (-2Q)

Grade D$2.31-22.1% Next Q

Q3 (-1Q)

Grade D$1.80-1.7% Next Q

Current

Grade D-$1.77-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MCRB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MCRB currently carries a cautious 40/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.51) and Max Pain ($1.86) forces dealer call-delta covering toward $31.48.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-0.68% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MCRB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MCRB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

MCRB Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (MCRB)

No recent open-market Form 4 cluster sales or emergency dumps flagged on MCRB. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MCRB)

✓Walkthrough of MCRB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MCRB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -76.98%🛡️ HOLDING TREND SUPPORT

2026-11-03O $1.95H $1.95L $1.77C $1.77VOL 120.1K

RES: $3.65SUP: $1.46SMA50: $3.51SMA200: $6.97

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MCRB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MCRB Butterfly Map → + Track MCRB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MCRB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MCRB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MCRB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MCRB)

Health Care Rank #470 of 1016 ⚔️ PBM vs MCRB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MCRB vs. PBM, ACTU, KYNB, AKTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Seres Therapeutics Inc. (MCRB) ranks #470 by composite RQD confidence (40/100, grade D-) and #837 by equity capitalization ($17.8M). Within this direct 5-issuer industry benchmark cohort, MCRB leads on earnings valuation at N/A trailing P/E, while MCRB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PBM currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with MCRB at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MCRB ACTIVE Seres Therapeutics Inc.	D-	40/100	—	—	-35.0%	-9.23%	$17.8M	Benchmark Subject
PBM Psyence Biomedical Ltd.	D	46/100	—	—	—	-8.31%	$17.6M	/pbm-vs-mcrb →
ACTU Actuate Therapeutics Inc.	D-	35/100	—	—	-35.0%	-9.68%	$18.4M	/actu-vs-mcrb →
KYNB Kyntra Bio Inc.	E	32/100	—	91.4%	-35.0%	-1.72%	$18.5M	/kynb-vs-mcrb →
AKTX Akari Therapeutics plc ADS	D-	37/100	—	—	-35.0%	+3.00%	$18.8M	/aktx-vs-mcrb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001609809

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Seres Therapeutics Inc. (MCRB) reported GAAP revenue of $789.0K (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $5.7M, operating cash flow of $1.1M, and free cash flow of $865.0K (+100.6% YoY). On the balance sheet, MCRB closed FY2025 with $138.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$789.0K	$5.7M	$1.1M	$865.0K	$138.2M	—
FY2024 (FY)	2024-12-31	$0	$136.0K	-$148.6M	-$149.0M	$139.8M	—
FY2023 (FY)	2023-12-31	$0	-$113.7M	-$117.4M	-$117.4M	—	—

3. MCRB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MCRB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MCRB compare to PBM and ACTU in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MCRB?

Where is MCRB trading relative to its 50-day, 200-day, and 52-week technical levels?

MCRB last traded at $1.77 (-9.23% on volume of 120,117 shares), positioning the stock -49.57% below its 50-day simple moving average ($3.51) and -74.61% below its 200-day simple moving average ($6.97). Across its 52-week range of $1.67 to $29.98, MCRB sits at the 0.4% percentile with a 14-day RSI of 26.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.55 to $1.99).

MCRB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are MCRB insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies MCRB leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: MCRB RQD Cockpit MCRB 12M Forecast MCRB Earnings & Move MCRB Dividends & DRIP MCRB Insiders & 13F MCRB Whale Options MCRB Profit Sankey MCRB News & Why

ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

MCRB — Seres Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:49:58Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, MCRB scores 40 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: the Fundamental Cash Engine scores 8 / 20 (ROIC -35%; FCF yield 4.42%), indicating weak capital efficiency and a negative return on invested capital. Whale 13F Flow scores 3 / 20 (institutional accumulation and options positioning), the lowest pillar, suggesting little supportive institutional demand in the data. Insider Conviction scores 10 / 20 (SEC Form 4 and Congressional PTR cluster flow). Macro Regime Fit scores 6 / 20 (Beta 1.0; sector sensitivity). Forensic Balance Sheet scores 13 / 20 (Altman Z 2.5; Piotroski F 5/9; Debt/Equity 0.5), the strongest pillar, though still moderate. For a prospective investor evaluating the stock today, the upside case rests on the cash position and the FCF yield rather than on operating profitability, while the main valuation tradeoff is that the operating margin of -60% and negative ROIC leave little earnings support for the current price. Institutional and flow signals are weak, so any re-rating would likely depend on company-specific catalysts rather than sponsorship.

Business

Seres Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, the market capitalization is $0.0B. Not available in source data for product lines, customer base, or revenue model detail.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.8M	$-94.0M	$5.7M	N/A	$0.9M	$45.8M	N/A
FY 2024	$0.0M	$-121.3M	$0.1M	N/A	$-149.0M	$30.8M	N/A
FY 2023	$0.0M	$-195.1M	$-113.7M	N/A	$-117.4M	N/A	N/A

Per the market data, the operating margin is -60% and the net margin is 68%, with a gross margin of 0%; the net margin figure is positive despite the negative operating income, a divergence the source does not explain. ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 5/9, and Debt/Equity is 0.5. Balance sheet posture is characterized by the forensic pillar score of 13 / 20; the source does not provide debt amounts beyond the ratio.

Recent Catalysts & News Wire Analysis

Executive departure (RISK WATCH, RED): Per the news feed, an announced resignation of Marella Thorell as Executive Vice President, effective November 15, 2026.
Preclinical data presentation (RISK WATCH, RED): Per the news feed, preclinical data for SER-428, an investigational live biotherapeutic, is to be presented at IDWeek 2026.
Results date (MARKET WIRE, YELLOW): Per the news feed, a results date of November 4 is set.
General market coverage (MARKET WIRE, YELLOW): Several aggregator items reference market action and institutional positioning without specific quantified content.
Per the market data, the stock moved +8.94% and traded 78,506 shares in volume.
Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals.

Open Questions

What is the composition and duration of the $45.8M cash balance relative to the operating burn implied by FY 2025 operating income of $-94.0M?
What explains the positive net margin (68%) and FY 2025 net income ($5.7M) against negative operating income?
What is the total debt amount, given the debt field is N/A and only a Debt/Equity ratio of 0.5 is given?
What are the clinical and regulatory milestones for SER-428 and the program timelines?
What drove the $1.67–$29.98 52-week range and the current price of $1.95?

MCRB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Seres Therapeutics Inc. (MCRB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MCRB Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance UK • 17h ago

Seres Therapeutics, Inc. (MCRB) Seasonal returns chart

Yahoo Finance UK report covering Seres Therapeutics Inc. (MCRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH www.marketscreener.com • 20h ago

Seres Therapeutics, Inc. Announces Resignation of Marella Thorell as Executive Vice President, Effective November 15, 2026

www.marketscreener.com report covering Seres Therapeutics Inc. (MCRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH GlobeNewswire • 23h ago

Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026

GlobeNewswire report covering Seres Therapeutics Inc. (MCRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Seres Therapeutics sets November 4 results date for MCRB stock

ad-hoc-news.de report covering Seres Therapeutics Inc. (MCRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Syfe • 1d ago

Marker Therapeutics, Inc. (MRKR) Stock Price & News

Syfe report covering Seres Therapeutics Inc. (MCRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Syfe • 1d ago

RNAZ Stock Price, Quote & News

Syfe report covering Seres Therapeutics Inc. (MCRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Seres Therapeutics stock quoted at EUR 1.74 late on October 29

ad-hoc-news.de report covering Seres Therapeutics Inc. (MCRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Syfe • 1d ago

Theriva Biologics, Inc. (TOVX) Stock Price & News

Syfe report covering Seres Therapeutics Inc. (MCRB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MCRB Bull vs. Bear Conversation Board — What's Your Call at $1.77?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MCRB 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.72 (-11.8%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is MCRB (D- • RQD 40/100) a Buy at $1.95?

Welcome to the MCRB (Seres Therapeutics Inc.) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.60 (-17.9%)

Spot @ $1.95

Pump the brakes on MCRB — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MCRB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Seres Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.36 (+21.0%)

Spot @ $1.95

MCRB cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MCRB, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.95 (52-wk range $1.67 - $29.98), any beat on forward guidance forces shorts and underweight funds to chase.